Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-04-19
2004-11-23
Leffers, Gerry (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S069100, C435S375000, C435S458000, C536S023100, C536S024100, C536S024500, C424S450000
Reexamination Certificate
active
06821956
ABSTRACT:
TECHNICAL FIELD
The field of this invention is therapeutic treatment of disease with double stranded nucleic acids which bind transcription factors.
BACKGROUND
A wide variety of diseases result from the over- or under-expression of one or more genes. Given cells may make insufficient amounts of a protein (e.g. insulin) or too much of a protein, be it a normal protein (e.g. TNF), a mutant protein (e.g. an oncogene), or a non-host protein (e.g. HIV tat). The ultimate goal of therapeutic intervention in such diseases is a selective modulation of gene expression.
A variety of methods of transcriptional modulation in vitro have been reported including the use of anti-sense nucleic acids capable of binding nascent message, intracellular immunization with dominant negative mutants.
With the broad potential therapeutic applications, massive efforts have been extended by prominent laboratories and clinics around the world to extend these methods in vivo. To date, the transcription factor decoy strategy has never been successfully adopted in vivo.
RELEVANT LITERATURE
Description of the roles of transcription factors may be found in Nevins,
Science
258, 424-429 (1992); Dalton,
EMBO J.
11, 11797 (1992); Yee et al. ibid. 6, 2061 (1987), Weintraub et al.,
Nature
358, 259-261 (1992), Pagano et al.,
Science
255, 1144-1147 (1992). Viral coat protein-liposome mediated transfection is described by Kaneda et al.,
Science
243, 375 (1989). Ritzenthaler et al. (1991)
Biochem J.
280, 157-162; Ritzenthaler et al (1993)
J Biol Chem
268, 13625-13631; Bielinska et al.,
Science
16, 997-1000 (1990) and Sullenger et al.,
Cell
63, 601-608 (1990) describe inhibition of transcription with double stranded nucleic acids.
A general discussion concerning the mechanism of restenosis may be found in Libby et al.,
Circulation
86, III-47 (1992) and Clowes et al.,
J. Cardiovasc. Pharmacol.
14, S12-15 (1989).
SUMMARY OF THE INVENTION
The invention provides for the therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. Methods and compositions are provided for blocking the capacity of endogenous trans-activating factors to modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection.
The methods comprise administering to a patient double stranded nucleic acid “decoys” in a form such that the decoys are capable of entering target cells of the patient and specifically binding an endogenous transcription factor, thereby competitively inhibiting the transcription factor from binding to an endogenous gene. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. Depending on the transcription factor, the methods can effect up- or down-regulation of gene expression. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.
REFERENCES:
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5631237 (1997-05-01), Dzau et al.
patent: 5683985 (1997-11-01), Chu et al.
patent: 5821234 (1998-10-01), Dzau
patent: 2003/0186922 (2003-10-01), Dzau et al.
patent: WO 91/11535 (1991-08-01), None
patent: WO 92/18522 (1992-10-01), None
patent: WO 93/03770 (1993-04-01), None
patent: WO 93/14768 (1993-08-01), None
patent: WO 95/11684 (1995-04-01), None
patent: WO 95/11687 (1995-05-01), None
Kawauchi et al. Gene Therapy for Attenuating Cardiac Allograft Arteriopathy Using Ex Vivo E2F Decoy Transfection by HVJ-AVE-Liposome Method in Mice and Nonhuman Primates. Circulation Research 1063-1068, Nov. 24, 2000.*
Dzau et al. Fusigenic viral liposomes for gene therapy in cardiovascular diseases. PNAS (93), pp 11421-11425, Oct., 1996.*
Morishita et al., A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle cell proliferation in vivo. PNAS (92), pp 5855-5859 Jun. 1995.*
Mann et al., Ex-vivo gene therapy oif human casular bypass grafts with E2F decoy: the PREVENT single centre, randomised controlled trial. The Lancet (354), pp 1493-1498, Oct. 30, 1999.*
Barinaga et al., “Gene Therapy for Clogged Arteries Passes Test in Pigs,” Science 265:738 (1994).
Bielinska et al., “Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides,” Science 250:997-999 (1990).
Chien, “Molecular Advances in Cardiovascular Biology,” Science 260:916-917 (1993).
Dalton, “Cell Cycle Regulation of the Human cdc2 Gene,” The EMBO Journal 11(5):1979-1804 (1992).
Ebbecke et al., European Heart Journal 12:11 (1991).
Hiebert et al., “E1A-dependent Trans-activation of the Human Myc Promoter is Mediated by the E2f Factor,” Proc. Natl. Acad. Sci. U. S. A. 86:3594-3598 (1989).
Hug et al., “Liposomes for the Transformation of Eukaryotic Cells,” Biochem. Biophys. Acta 1097:1-17 (1991).
Hutchinson et al., Circulation 86:Suppl. I p. I -226 (1992).
Kaneda et al., “Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver,” Science 243:375-378 (1989).
Libby et al., “A Cascade Model for Restenosis. A Special Case of Atheroscerosis Progression,” Circulation 86:III-47-III-52 (1992).
Mannino et al., “Liposome Mediated Gene Transfer,” BioTechniques 6:682-690 (1988).
Milligan et al., “Current Concepts in Antisense Drug Design,” J. Med. Chem. 36:1923-1937 (1993).
Morishita et al., “In Vivo Gene Transfer into intact Blood Vessels: a Novel and Efficient Method,” Circulation 86 (Suppl. I):1-227 (1992).
Mulligan et al., “The Basic Science of Gene Therapy,” Science 260:926-932 (1993).
Nevins, “E2F: A Link Between the Rb Tumor Supressor Protein and Viral Oncoproteins,” Science 258:424-429 (1992).
Ostrowski et al., “Glucocorticoid Regulation of Transcription at an Amplified, Episomal Promoter,” Mol. Cell. Biol. 3:2045-2057 (1983).
Pagano et al., “Association of cdk2 Kinase with the Transcription Factor E2F During S Phase,” Science 255:1144-1147 (1992).
Ritzenthaler et al., “Regulation of the &agr;1(I) Collagen Promoter via a Transforming Growth Factor-&bgr;Activation Element,” J. Biol. Chem. 268:13625-13631 (1993).
Ritzenthaler et al., “Transforming-growth-factor-&bgr; Activation Elements in the Distal Promoter Regions of the Rat &agr;1 Type I Collagen Gene,” Biochem. J. 280:157-162 (1991).
Rubin et al., “Atherosclerosis in Mice: Getting to the Heart of a Polygenic Disorder.” Trends in Genetics 10:199-204 (1994).
Schwartz et al., “Coronary Restenosis: Prospects for Solution and New Perspectives from a Porcine Model,” Mayo Clinic Proceedings 68:54-62 (1993).
Stein et al., “Antisense Oligonucleotides as Therapeutic Agents—is the Bullet Really Magical?” Science 261:1004-12 (1993).
Sullenger et al., “Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication,” Cell 63:601-608 (1990).
Tomita et al., “Direct in Vivo Gene Introduction into Rat Kidney,” Biochem. Biophys. Res. Comm. 186:129-134 (1992).
Tseng et al., “Antisense Oligonucleotide Technology in the Development of Caner Therapeutics,” Cancer Gene Ther. 1:65-71 (1994).
Uhlmann et al., Chemical Reviews 90:543-584 (1990).
Weintraub et al., “Retinoblastoma Protein Switches the E2F Site from Positive to Negative Element,” Nature 358:259-261 (1992).
Wu et al., “Inhibition of In Vitro Transcription by Specific Double-stranded Oligodeoxyribonucleotides,” Gene 89:203-209 (1990).
Yee et al., “Promoter Interaction of the E1A-inducible Factor E2F and its Potential Role in the Formation of a Multi-component Complex,” The EMBO Journal 6:2061-2068 (1987).
Chu et al., “The Stability of Different Forms of Double-stranded Decoy DNA in Serum and Nuclear Extracts,” Nucleic Acids Research 20:5857-5858 (1992).
Eck et al., “Inhibition of Phorbol Ester-Induce
Dzau Victor J.
Gibbons Gary H.
Morishita Ryuichi
Dreger Ginger R.
Heller Ehrman White & McAuliffe LLP
Leffers Gerry
Marvich Maria
The Brigham and Women's Hospital Inc.
LandOfFree
Therapeutic use of cis-element decoys in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of cis-element decoys in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of cis-element decoys in vivo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3280212